- Home
- GILD vs ANET Comparison
GILD vs ANET Comparison
Compare GILD & ANET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | ANET |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Communications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.9B | 165.1B |
| IPO Year | 1992 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GILD | ANET |
|---|---|---|
| Price | $124.79 | $131.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 15 |
| Target Price | $127.60 | ★ $163.00 |
| AVG Volume (30 Days) | ★ 7.0M | 5.9M |
| Earning Date | 02-10-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ 6514.05 | 26.15 |
| EPS | ★ 6.42 | 2.63 |
| Revenue | ★ $29,087,000,000.00 | $8,448,346,000.00 |
| Revenue This Year | $3.63 | $29.46 |
| Revenue Next Year | $3.10 | $21.86 |
| P/E Ratio | ★ $19.57 | $49.73 |
| Revenue Growth | 2.79 | ★ 27.75 |
| 52 Week Low | $88.57 | $59.43 |
| 52 Week High | $128.70 | $164.94 |
Technical Indicators
Market Signals| Indicator | GILD | ANET |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 52.48 |
| Support Level | $118.17 | $129.25 |
| Resistance Level | $127.41 | $134.00 |
| Average True Range (ATR) | 2.85 | 4.48 |
| MACD | 0.36 | 1.05 |
| Stochastic Oscillator | 70.11 | 69.26 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.